A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India
Sponsor: Cipla Ltd.
Listed as NCT06370715, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Cipla Ltd., it has been updated 11 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Aug 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE4
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE4
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE4
▶ Show 6 earlier versions
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE4
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cipla Ltd.
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Bengaluru, India , Bikaner, India , Coimbatore, India , Hyderabad, India , Jaipur, India , Kanpur, India , Kolkata, India , Pune, India , Royapuram, India and 1 more location